173 related articles for article (PubMed ID: 35216667)
1. Fumarate inhibits PTEN to promote tumorigenesis and therapeutic resistance of type2 papillary renal cell carcinoma.
Ge X; Li M; Yin J; Shi Z; Fu Y; Zhao N; Chen H; Meng L; Li X; Hu Z; Zhao X; Guo H; Qian X
Mol Cell; 2022 Apr; 82(7):1249-1260.e7. PubMed ID: 35216667
[TBL] [Abstract][Full Text] [Related]
2. Circling back to PTEN: Fumarate inhibits canonical tumor suppressor.
Claridge SE; Hopkins BD
Mol Cell; 2022 Apr; 82(7):1244-1245. PubMed ID: 35395197
[TBL] [Abstract][Full Text] [Related]
3. Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models.
Qian CN; Furge KA; Knol J; Huang D; Chen J; Dykema KJ; Kort EJ; Massie A; Khoo SK; Vanden Beldt K; Resau JH; Anema J; Kahnoski RJ; Morreau H; Camparo P; Comperat E; Sibony M; Denoux Y; Molinie V; Vieillefond A; Eng C; Williams BO; Teh BT
Cancer Res; 2009 Nov; 69(21):8256-64. PubMed ID: 19843858
[TBL] [Abstract][Full Text] [Related]
4. Reduced expression of fumarate hydratase in clear cell renal cancer mediates HIF-2α accumulation and promotes migration and invasion.
Sudarshan S; Shanmugasundaram K; Naylor SL; Lin S; Livi CB; O'Neill CF; Parekh DJ; Yeh IT; Sun LZ; Block K
PLoS One; 2011; 6(6):e21037. PubMed ID: 21695080
[TBL] [Abstract][Full Text] [Related]
5. Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC.
Yamasaki T; Tran TA; Oz OK; Raj GV; Schwarz RE; Deberardinis RJ; Zhang X; Brugarolas J
Nat Rev Urol; 2011 Mar; 8(3):165-71. PubMed ID: 21304509
[TBL] [Abstract][Full Text] [Related]
6. mTORC1 Upregulation Leads to Accumulation of the Oncometabolite Fumarate in a Mouse Model of Renal Cell Carcinoma.
Drusian L; Nigro EA; Mannella V; Pagliarini R; Pema M; Costa ASH; Benigni F; Larcher A; Chiaravalli M; Gaude E; Montorsi F; Capitanio U; Musco G; Frezza C; Boletta A
Cell Rep; 2018 Jul; 24(5):1093-1104.e6. PubMed ID: 30067967
[TBL] [Abstract][Full Text] [Related]
7. Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status.
Bardella C; El-Bahrawy M; Frizzell N; Adam J; Ternette N; Hatipoglu E; Howarth K; O'Flaherty L; Roberts I; Turner G; Taylor J; Giaslakiotis K; Macaulay VM; Harris AL; Chandra A; Lehtonen HJ; Launonen V; Aaltonen LA; Pugh CW; Mihai R; Trudgian D; Kessler B; Baynes JW; Ratcliffe PJ; Tomlinson IP; Pollard PJ
J Pathol; 2011 Sep; 225(1):4-11. PubMed ID: 21630274
[TBL] [Abstract][Full Text] [Related]
8. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma.
Ooi A; Wong JC; Petillo D; Roossien D; Perrier-Trudova V; Whitten D; Min BW; Tan MH; Zhang Z; Yang XJ; Zhou M; Gardie B; Molinié V; Richard S; Tan PH; Teh BT; Furge KA
Cancer Cell; 2011 Oct; 20(4):511-23. PubMed ID: 22014576
[TBL] [Abstract][Full Text] [Related]
9. Co-existence of high levels of the PTEN protein with enhanced Akt activation in renal cell carcinoma.
He L; Fan C; Gillis A; Feng X; Sanatani M; Hotte S; Kapoor A; Tang D
Biochim Biophys Acta; 2007 Oct; 1772(10):1134-42. PubMed ID: 17681738
[TBL] [Abstract][Full Text] [Related]
10. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability.
Isaacs JS; Jung YJ; Mole DR; Lee S; Torres-Cabala C; Chung YL; Merino M; Trepel J; Zbar B; Toro J; Ratcliffe PJ; Linehan WM; Neckers L
Cancer Cell; 2005 Aug; 8(2):143-53. PubMed ID: 16098467
[TBL] [Abstract][Full Text] [Related]
11. Fumarate Hydratase-deficient Cell Line NCCFH1 as a New In Vitro Model of Hereditary Papillary Renal Cell Carcinoma Type 2.
Perrier-Trudova V; Huimin BW; Kongpetch S; Huang D; Ong P; Le Formal A; Poon SL; Siew EY; Myint SS; Gad S; Gardie B; Couvé S; Foong YM; Choudhury Y; Poh J; Ong CK; Toh CK; Ooi A; Richard S; Tan MH; Teh BT
Anticancer Res; 2015 Dec; 35(12):6639-53. PubMed ID: 26637880
[TBL] [Abstract][Full Text] [Related]
12. miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma.
Sekino Y; Sakamoto N; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
Oncology; 2019; 97(3):164-172. PubMed ID: 31195398
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mitochondrial aconitase by succination in fumarate hydratase deficiency.
Ternette N; Yang M; Laroyia M; Kitagawa M; O'Flaherty L; Wolhulter K; Igarashi K; Saito K; Kato K; Fischer R; Berquand A; Kessler BM; Lappin T; Frizzell N; Soga T; Adam J; Pollard PJ
Cell Rep; 2013 Mar; 3(3):689-700. PubMed ID: 23499446
[TBL] [Abstract][Full Text] [Related]
14. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.
Petrella BL; Brinckerhoff CE
Cancer Biol Ther; 2009 Jul; 8(14):1389-401. PubMed ID: 19483472
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathological characteristics of fumarate hydratase-deficient renal cell carcinoma].
Zhang W; Chu J; Zou YW; Jiang YX; Wei ZM; Zhong DC; Liu Y; Li YJ; Yu WJ
Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):120-126. PubMed ID: 30695864
[No Abstract] [Full Text] [Related]
16. Relevance and therapeutic possibility of PTEN-long in renal cell carcinoma.
Wang H; Zhang P; Lin C; Yu Q; Wu J; Wang L; Cui Y; Wang K; Gao Z; Li H
PLoS One; 2015; 10(2):e114250. PubMed ID: 25714556
[TBL] [Abstract][Full Text] [Related]
17. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.
Yang Y; Valera VA; Padilla-Nash HM; Sourbier C; Vocke CD; Vira MA; Abu-Asab MS; Bratslavsky G; Tsokos M; Merino MJ; Pinto PA; Srinivasan R; Ried T; Neckers L; Linehan WM
Cancer Genet Cytogenet; 2010 Jan; 196(1):45-55. PubMed ID: 19963135
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous adaptation of cysteine reactivity to a covalent oncometabolite.
Perez M; Bak DW; Bergholtz SE; Crooks DR; Arimilli BS; Yang Y; Weerapana E; Linehan WM; Meier JL
J Biol Chem; 2020 Sep; 295(39):13410-13418. PubMed ID: 32820045
[TBL] [Abstract][Full Text] [Related]
19. Incidence of succinate dehydrogenase and fumarate hydratase-deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC.
Gupta S; Swanson AA; Chen YB; Lopez T; Milosevic D; Kipp BR; Leibovich BC; Thompson RH; Herrera-Hernandez L; Cheville JC; Jimenez RE
Hum Pathol; 2019 Sep; 91():114-122. PubMed ID: 31299266
[TBL] [Abstract][Full Text] [Related]
20. miR-96-5p targets PTEN to mediate sunitinib resistance in clear cell renal cell carcinoma.
Park SE; Kim W; Hong JY; Kang D; Park S; Suh J; You D; Park YY; Suh N; Hwang JJ; Kim CS
Sci Rep; 2022 Mar; 12(1):3537. PubMed ID: 35241735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
